TrialArthritis research & therapy2015

Reanalysis of the Rituximab in ANCA-Associated Vasculitis trial identifies granulocyte subsets as a novel early marker of successful treatment.

Mazen Nasrallah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.